Value of Colonoscopy for Prediction of Prognosis in Patients with Ulcerative Colitis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 Apr 15

PMID 18407585

Citations 6

Authors

Takafumi Ando

Yuji Nishio

Osamu Watanabe

Hironao Takahashi

Osamu Maeda

Kazuhiro Ishiguro

Daisuke Ishikawa

Naoki Ohmiya

Yasumasa Niwa

Hidemi Goto

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by exacerbations and remissions. Some UC patients remain refractory to conventional medical treatment while, in others, the effectiveness of drugs is limited by side-effects. Recently, cyclosporine and leukocyte removal therapy have been used for refractory UC patients. To predict the efficacy of these therapies is important for appropriate selection of treatment options and for preparation for colectomy. Endoscopy is the cornerstone for diagnosis and evaluation of UC. Endoscopic parameters in patients with severe or refractory UC may predict a clinical response to therapies, such as cyclosporine or leukocyte removal therapy. As for the patients with quiescent UC, relapse of UC is difficult to predict by routine colonoscopy. Even when routine colonoscopy suggests remission and a normal mucosal appearance, microscopic abnormalities may persist and relapse may occur later. To more accurately identify disease activity and to predict exacerbations in UC patients with clinically inactive disease is important for deciding whether medical treatment should be maintained. Magnifying colonoscopy is useful for the evaluation of disease activity and for predicting relapse in patients with UC.

Citing Articles

Predictive models for endoscopic disease activity in patients with ulcerative colitis: Practical machine learning-based modeling and interpretation.

Li X, Yan L, Wang X, Ouyang C, Wang C, Chao J Front Med (Lausanne). 2023; 9:1043412.

PMID: 36619650 PMC: 9810755. DOI: 10.3389/fmed.2022.1043412.

Advances in Imaging Specific Mediators of Inflammatory Bowel Disease.

Dmochowska N, Wardill H, Hughes P Int J Mol Sci. 2018; 19(9).

PMID: 30134572 PMC: 6164364. DOI: 10.3390/ijms19092471.

How to predict clinical relapse in inflammatory bowel disease patients.

Liverani E, Scaioli E, Digby R, Bellanova M, Belluzzi A World J Gastroenterol. 2016; 22(3):1017-33.

PMID: 26811644 PMC: 4716017. DOI: 10.3748/wjg.v22.i3.1017.

Ulcerative colitis six years after colon cancer: only a coincidence?.

Sakellakis M, Makatsoris T, Gkermpesi M, Peroukidis S, Kalofonos H Int Med Case Rep J. 2014; 7:85-8.

PMID: 24855393 PMC: 4011808. DOI: 10.2147/IMCRJ.S61950.

Transparent cap colonoscopy versus standard colonoscopy to improve caecal intubation.

Morgan J, Thomas K, Lee-Robichaud H, Nelson R, Braungart S Cochrane Database Syst Rev. 2012; 12:CD008211.

PMID: 23235654 PMC: 7105905. DOI: 10.1002/14651858.CD008211.pub3.

References

Cohen R . Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone?. Gastroenterology. 2001; 120(6):1541-3. DOI: 10.1053/gast.2001.24398. View

Descos L, Andre F, Andre C, Gillon J, Landais P, Fermanian J . Assessment of appropriate laboratory measurements to reflect the degree of activity of ulcerative colitis. Digestion. 1983; 28(2):148-52. DOI: 10.1159/000198978. View

ROWE F, Walker J, Karp L, Vasiliauskas E, Plevy S, Targan S . Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol. 2000; 95(8):2000-8. DOI: 10.1111/j.1572-0241.2000.02186.x. View

Sawada K, Ohnishi K, Kosaka T, Fukui S, Yamamura M, Amano K . Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol. 1995; 30 Suppl 8:124-7. View

TRUELOVE S, Richards W . Biopsy studies in ulcerative colitis. Br Med J. 1956; 1(4979):1315-8. PMC: 1980058. DOI: 10.1136/bmj.1.4979.1315. View

Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y . Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2004; 1(1):28-35. DOI: 10.1053/jcgh.2003.50005. View

Hurlstone D, Cross S, Adam I, Shorthouse A, Brown S, Sanders D . Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis. Gut. 2004; 53(2):284-90. PMC: 1774917. DOI: 10.1136/gut.2003.027623. View

George J, Present D, Pou R, Bodian C, Rubin P . The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996; 91(9):1711-4. View

Stack W, Long R, Hawkey C . Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther. 1998; 12(10):973-8. DOI: 10.1046/j.1365-2036.1998.00396.x. View

10.

Edwards S, Hallett M . Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today. 1997; 18(7):320-4. DOI: 10.1016/s0167-5699(97)01087-6. View

11.

Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J . Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000; 14(3):273-9. DOI: 10.1046/j.1365-2036.2000.00705.x. View

12.

Lichtiger S . Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med. 1990; 57(5):315-9. View

13.

Rao S, HOLDSWORTH C, Read N . Symptoms and stool patterns in patients with ulcerative colitis. Gut. 1988; 29(3):342-5. PMC: 1433596. DOI: 10.1136/gut.29.3.342. View

14.

Binder V . A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa, and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol. 1970; 5(7):627-32. View

15.

Levine T, Tzardi M, Mitchell S, Sowter C, Price A . Diagnostic difficulty arising from rectal recovery in ulcerative colitis. J Clin Pathol. 1996; 49(4):319-23. PMC: 500459. DOI: 10.1136/jcp.49.4.319. View

16.

Korelitz B, SOMMERS S . Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975; 64(5):365-70. View

17.

Kurtel H, Granger D, Tso P, Grisham M . Vulnerability of intestinal interstitial fluid to oxidant stress. Am J Physiol. 1992; 263(4 Pt 1):G573-8. DOI: 10.1152/ajpgi.1992.263.4.G573. View

18.

Daniel F, Loriot M, Seksik P, Cosnes J, Gornet J, Lemann M . Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007; 13(1):19-23. DOI: 10.1002/ibd.20046. View

19.

Riley S, Mani V, GOODMAN M, Herd M, Dutt S, Turnberg L . Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988; 29(5):669-74. PMC: 1433642. DOI: 10.1136/gut.29.5.669. View

20.

Kudo S, Rubio C, Teixeira C, Kashida H, Kogure E . Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy. 2001; 33(4):367-73. DOI: 10.1055/s-2004-826104. View